drugset / Trial / NCT07466953

Objective Evaluation of Intradermal MSC-Derived Exosome Therapy on Facial Skin Quality

NCT07466953 ↗

Phase 3 Not yet recruiting 30 enrolled Mert Ersan
NaSingle-groupOpen-labelTreatment

Summary

This study aims to evaluate the potential effects of mesenchymal stem cell-derived suspended exosome therapy on facial skin quality using objective imaging analysis. Thirty adult participants will receive intradermal exosome applications in three treatment sessions performed at one-month intervals. Facial skin analysis will be conducted using the VISIA imaging system before each treatment session and six months after the final treatment. The study will examine changes in multiple facial skin characteristics including wrinkles, pigmentation, skin texture, pores, UV spots, red areas, brown spots, and porphyrins to determine whether exosome therapy may improve overall facial skin quality.

Timeline

Start
2026-04-01
Primary completion
2026-12-01
Completion
2026-12-31

Drugs

EvaluationDrugModalityDoseRoute
Subject Mesenchymal Stem Cell-Derived Exosome Other / unclassified 5 ml Other

Indications

No indication recorded.